Characteristics of all MSM at first consultation in study period; Amsterdam Centre for Sexual Health, July 2018–July 2019
| Variables | Total (n=11,594) | Infectious syphilis (n=274) | No infectious syphilis (n=11,320) | P value |
| Age in years (median, IQR) | 34 (27–45) | 36 (29–47) | 34 (27–45) | 0.009 |
| Country of birth, n (%) | ||||
| Netherlands | 7,332 (63.2) | 155 (56.6) | 7,177 (63.4) | 0.020 |
| Othe4,r | 4,262 (36.8) | 119 (43.4) | 4,143 (36.6) | |
| Sexual behaviour, n (%) | ||||
| MSM | 10,237 (88.3) | 260 (94.9) | 9,977 (88.1) | 0.001 |
| MSMW | 1,357 (11.7) | 14 (5.1) | 1,343 (11.9) | |
| HIV status, n (%) | ||||
| Negative | 10,005 (86.3) | 152 (55.5) | 9,853(87.0) | <0.001 |
| Positive | 1,586 (13.7) | 122 (44.5) | 1,464 (12.9) | |
| Unknown | 3 (0.0) | 3 (0.0) | 0 (0.0) | |
| On ART, n (%)* | 1,396 (93.0) | 103 (89.6) | 1,293 (93.3) | 0.132 |
| HIV VL as reported by patient, n (%) | ||||
| Undetectable | 1,379 (86.9) | 105 (86.1) | 1,274 (87.0) | <0.001 |
| Detectable | 33 (2.1) | 3 (2.5) | 30 (2.0) | |
| Notified for syphilis | 421 (3.6) | 56 (20.4) | 365 (3.2) | <0.001 |
| STD diagnosis at current visit, n (%) | ||||
| Chlamydia | 1,146 (9.9) | 52 (19.0) | 1,094 (9.7) | <0.001 |
| Gonorrhoea | 1,290 (11.1) | 62 (22.6) | 1,228 (10.9) | <0.001 |
| Lymphogranuloma venereum | 73 (0.6) | 8 (2.9) | 65 (0.6) | <0.001 |
| Hepatitis B | 9 (0.1) | 1 (0.4) | 8 (0.1) | 0.084 |
| Hepatitis C | 3 (0) | 0 (0) | 3 (0) | 0.788 |
*For those who are HIV positive, data on ART use of 85 participants were missing.
ART, antiretroviral therapy; IQR, interquartile range; MSM, men who have sex with men; MSMW, men who have sex with men and women; STD, sexually transmitted disease; VL, viral load.